NR-607 Week 5 tends to reach the pharmacology of the hardest charts: the patient who has not responded, the regimen that has grown by accretion, and the decision to augment, switch or subtract. The written skill is the audit, proving a treatment actually failed before reacting to the failure. Your section may print this as NR 607 or NR607; it is the same course. Chamberlain publishes no syllabi outside Canvas. The placement here is our teaching judgment from the course's catalog arc; your section's rubric decides what your week actually asks.
Medication decisions in your practicum run under your preceptor's license and your site's rules, and nothing about coursework support changes that: the prescribing, the hours and the clinical record are yours and theirs. The paper analyzing those decisions is the deliverable this page is about.
What NR-607 Week 5 asks for
Expect the territory to cover the anatomy of non-response: pseudo-resistance from inadequate dose, inadequate duration, missed adherence or a wrong diagnosis, against true resistance that has survived genuine trials. From there the week usually opens the working questions of complex psychopharmacology, augmentation against switching, interactions in a regimen that has accumulated agents, monitoring burden as a real cost, and the deprescribing conversation nobody schedules.
Common deliverable shapes are a medication management paper built around one complex regimen, an analysis of a supplied treatment-resistant vignette, or a proposal defending a single regimen change with its monitoring plan. If your section runs a discussion this week, it often asks what you would change first in an inherited five-drug chart, a question designed to reveal who audits before acting.
Your week's rubric will likely pay most for the arithmetic of failure: doses reached, weeks held, adherence verified, and only then a change proposed with its mechanism and its exit criteria written down.
The NR-607 Week 5 method, step by step
Six moves from an inherited regimen to a defensible change.
-
Audit every prior trial like an accountant
For each agent tried: the highest dose reached, the weeks held at that dose, the response observed, the reason it ended. A trial that never hit an adequate dose for an adequate duration is not a failure, and your table should say so.
-
Verify adherence before believing the failure
Say how adherence was assessed: patient report, refill history, collateral, levels where they exist. Non-response with unverified adherence is a hypothesis, not a finding, and papers that skip this step build on sand.
-
Reopen the diagnosis once
Resistance is sometimes the wrong label answered correctly. Give one paragraph to whether the target diagnosis still fits, whether a use disorder or medical contributor is driving the picture, and what that reconsideration returned.
-
Choose augment or switch and defend the fork
State the option you take, the mechanism you expect to add, and why the other fork lost: partial response argues one way, no response argues the other, and your sentence should show you know which situation you are in.
-
Run the interaction and monitoring math
Name the interactions the new combination creates, the parameters to watch, the baseline values needed, and the intervals. A proposal without its monitoring plan is half a proposal at this level.
-
Define response before you leave the page
Write the criteria, the instrument or observation that will measure them, and the review date at which the change is kept or unwound. Then format: current APA, generic names used consistently, headings in your rubric's wording.
A medication decision paper, section by section
Targets assume roughly 1,400 words for a single-regimen analysis. Rescale to your prompt; the audit and the proposal should stay the two largest blocks.
| Section | What belongs there | Word target |
|---|---|---|
| The patient and the regimen inherited | The de-identified case, the current agents with doses, and how the regimen accumulated | 180 to 220 |
| The trial audit | Every prior agent with dose reached, duration held, response and end reason | 280 to 330 |
| Adherence and tolerability record | How adherence was verified and what side effects shaped the history | 150 to 190 |
| Diagnostic reconsideration | Whether the target diagnosis survives review, and the contributors examined | 150 to 190 |
| The change proposed | Augment or switch, the mechanism added, the fork defended, doses and titration | 260 to 310 |
| Monitoring and response criteria | Interactions named, parameters and intervals set, response defined with its review date | 200 to 250 |
Notice what is absent: a section praising the new agent. The evidence for the change belongs inside the proposal, attached to the mechanism and the fork, not in a free-floating literature review.
Citing augmentation evidence at its real strength
Augmentation and switching literature is a mix of randomized trials, open-label extensions and case series, and the mix is the point: say which kind of study supports each claim, with the sample size and population in the sentence. A strategy supported by a randomized trial of a few hundred patients and one supported by a case series of eleven deserve different verbs, and your prose should award them accordingly.
Quote effect sizes rather than verdicts where the studies give them, and keep the comparator visible: better than placebo is not better than the alternative strategy, and papers that blur that line lose the evidence row quietly. Where a recognized treatment algorithm or guideline organizes this territory, cite the issuing body and year in the running text and use it as a frame, not as a substitute for reasoning about your specific patient.
Numbers about your own case follow the same rules. Weeks at dose, score changes on a named instrument, refill gaps in days: measured quantities, each with its window. "Some improvement" is an impression; a four-point change over six weeks on a named scale is a finding.
Five mistakes that cost points in a resistance week
- Resistance declared without the audit. If the paper cannot show adequate dose and duration for the failed trials, the premise of every later section is unproven.
- Adding without subtracting. A proposal that grows the regimen while never addressing what should leave reads as accumulation, the exact habit the week critiques.
- Mechanism recited instead of reasoned. A receptor paragraph copied from a reference belongs nowhere; the graded move is connecting the mechanism to this patient's failed trials.
- Monitoring waved at. "Will monitor closely" is not a plan. Parameters, baselines, intervals and the person responsible make it one.
- Response left undefined. Without written criteria and a review date, the change can never fail, which means it was never really a clinical decision.
Before you submit
- Every prior trial shows dose, duration, response and end reason
- Adherence verification is described, not assumed
- The diagnosis got one honest paragraph of reconsideration
- The augment-versus-switch fork is argued from this patient's response pattern
- Interactions, parameters, baselines and intervals are all named
- Response criteria and the review date are in writing
Complex regimen paper stalling?
Send the med history shape and your rubric. A draft with the audit table built and the fork argued returns inside 24 to 48 hours, revised free until it lands.